FDA grants accelerated approval for ibrutinib for CLL.


The US Food and Drug Administration (FDA) on Wednesday granted accelerated approval for the expanded use of ibrutinib, marketed as Imbruvica, for chronic lymphocytic leukemia (CLL) patients who have previously received at least one therapy. This approval was based on a phase 1b-2 open-label, multicenter study that was designed to determine the safety… (More)


Figures and Tables

Sorry, we couldn't extract any figures or tables for this paper.

Slides referencing similar topics